SCT-200 is under clinical development by SinoCelltech Group and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SCT-200’s likelihood of approval (LoA) and phase transition for Recurrent Head And Neck Cancer Squamous Cell Carcinoma took place on 28 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SCT-200 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SCT-200 is under development for the treatment of metastatic colorectal cancer, metastatic triple negative breast cancer, esophageal squamous cell carcinoma, squamous non-small cell lung cancer and recurrent head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The drug candidate is a monoclonal antibody. It acts by targeting the epidermal growth factor receptor (EGFR).
It was under development for the treatment of lymphoma, solid tumors including gastric cancer/gastroesophageal junction cancer, hepatocellular carcinoma, pancreatic cancer, bile duct/gallbladder cancer, renal cell carcinoma and ovarian cancer
SinoCelltech Group overview
SinoCelltech Group (SinoCelltech), formerly Beijing Shenzhou Cell Biotechnology Group, is a biopharmaceutical company that discovers, develops monoclonal antibodies, vaccines and recombinant proteins for treatment of cancer, psoriasis and rheumatoid arthritis. SinoCelltech’s pipeline products include SCT200, a human EGFR monoclonal antibody for colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma and other solid tumors; SCT400, a human-mouse chimeric anti-CD20 monoclonal antibody indicated for non-Hodgkin’s lymphoma; SCT510, a biosimilar of bevacizumab developed for the treatment of non-small cell lung cancer and colorectal cancer; SCT-I10A, a humanized anti-PD-1 IgG4 monoclonal antibody indicated for esophageal squamous cell carcinoma, gastric adenocarcinoma. The company is also evaluating drug candidates targeting for treatment of psoriasis, rheumatoid arthritis and ankylosing spondylitis. SinoCelltech is headquartered in Beijing, China.
Quick View SCT-200 LOA Data
|Highest Development Stage|